HLOC
VRTX icon

H.L. Ormond & Company’s Vertex Pharmaceuticals VRTX Stock Holding History

H.L. Ormond & Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$329K Buy
1,139
+190
+20% +$54.7K 0.53% 74
2022
Q2 		$267K Sell
949
-383
-29% -$103K 0.43% 77
2022
Q1 		$348K Sell
1,332
-10
-0.7% -$2.37K 0.42% 81
2021
Q4 		$323K Buy
+1,342
New +$261K 0.38% 86

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

H.L. Ormond & Company's VRTX Position: Q3 2022 in Review

H.L. Ormond & Company increased its Vertex Pharmaceuticals (VRTX) stake by 20% in Q3 2022, buying an estimated $54.7K and bringing the position to 1,139 shares worth $329K. The position accounts for 0.53% of the portfolio, ranked #74.

H.L. Ormond & Company first reported a position in VRTX in Q4 2021 and has held it in 4 quarters since. The position peaked at $348K in Q1 2022. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

  • H.L. Ormond & Company held 1,139 shares of Vertex Pharmaceuticals worth $329K as of Q3 2022.
  • H.L. Ormond & Company bought 190 Vertex Pharmaceuticals shares in Q3 2022, an estimated $54.7K.
  • Vertex Pharmaceuticals made up 0.53% of H.L. Ormond & Company's portfolio in Q3 2022, its #74 holding.
  • H.L. Ormond & Company first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
  • H.L. Ormond & Company's Vertex Pharmaceuticals position peaked at $348K in Q1 2022.
  • 1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on H.L. Ormond & Company's 13F filing for Q3 2022, filed 14 Nov 2022.